Study at a glance
Do combined vitamin D and K supplements improve bones or calcium buildup?
This page reviews human studies of vitamin D and vitamin K in bone health and unwanted calcium deposits. It distinguishes changes in blood markers from changes in bone structure, fractures or disease. Improving a protein marker does not automatically mean that bones become stronger or calcium buildup slows.
What did studies of vitamins D and K find about bone density?
Some trials in women after menopause found improved bone mineral density with combined treatment. A review of eight trials involving 971 people found higher bone density and improvement in a vitamin K-dependent bone-protein marker. However, doses, vitamin forms and other supplements varied. In a separate analysis of generally healthy middle-aged and older adults, better starting vitamin K status did not reveal a bone-density benefit from vitamin D supplementation.
Did vitamins D and K slow calcium buildup in the heart valve?
A trial in 365 older men with substantial calcium buildup in the aortic heart valve compared vitamin K2 plus vitamin D with an inactive treatment for two years. A blood marker of inactive matrix Gla protein, which helps control unwanted mineral deposits, improved. Yet valve calcium buildup did not slow significantly overall. A later coronary-artery analysis suggested benefit in a smaller group with high starting calcium scores, but the overall result was not significant.
Do these findings show benefits from vitamins D and K for everyone?
The smaller-group result needs confirmation. Findings in children receiving dialysis also showed protein-marker changes, but cannot be assumed to apply to healthy adults. The evidence does not establish consistent bone or blood-vessel benefits for everyone taking both vitamins. It also does not show that vitamin K prevents toxicity or high blood calcium caused by excessive vitamin D.
Read the full article below ↓The mechanistic relationship between vitamin D and vitamin K creates a plausible reason to study them together, but clinical trials are required to determine whether combining the nutrients improves bone or vascular outcomes. Human intervention evidence is mixed. Some trials in postmenopausal women show improvements in bone mineral density or undercarboxylated osteocalcin when vitamin K is added to vitamin D and calcium. Other large or more recent studies show that favourable changes in vitamin-K-dependent protein biomarkers do not necessarily translate into slower bone loss or reduced vascular calcification. This difference between mechanism, biomarker and structural outcome is central to interpreting Vitamin D and Vitamin K. For a shorter version, see Combined Vitamin D and Vitamin K Supplementation for Bone and Vascular Markers: Study Summary.
Early combination trials focused mainly on bone
Several early intervention studies tested vitamin K₂ together with vitamin D in postmenopausal osteoporosis. These trials were generally much smaller than modern cardiovascular outcome trials and often used pharmacological doses or vitamin D analogues rather than ordinary nutritional supplementation.
One randomized study included 92 postmenopausal women with osteoporosis divided among vitamin D₃, vitamin K₂, combined vitamin D₃ plus K₂, and calcium groups. Over two years, the combined group showed a larger increase in lumbar-spine bone mineral density than the comparator groups.
A separate randomized study in 172 women with low vertebral bone density reported an approximately 4.9% increase in bone mineral density after two years of combined K₂ and D₃ therapy. These studies support biological plausibility for combination treatment in particular osteoporosis populations, but their formulations and clinical context limit direct translation to general supplementation.
Adding vitamin K can strongly change osteocalcin carboxylation
A Korean randomized intervention in older postmenopausal women compared vitamin K₂ plus vitamin D and calcium with vitamin D plus calcium. After six months, undercarboxylated osteocalcin fell more strongly in the vitamin-K group, while lumbar L3 bone mineral density increased relative to control in the per-protocol analysis.
The undercarboxylated osteocalcin result is important because it directly reflects the vitamin-K-dependent step. Vitamin D can stimulate osteocalcin production, but carboxylation requires vitamin K. A reduction in undercarboxylated osteocalcin therefore demonstrates that the combination can change the functional state of a vitamin-K-dependent bone protein.
However, a biomarker change and a fracture outcome are not equivalent. Bone mineral density, microarchitecture, falls, fractures and bone strength represent different levels of clinical evidence. The wider bone context belongs within Vitamin D and Bone.
Meta-analysis supports a bone signal but does not settle every outcome
A meta-analysis of eight randomized controlled trials involving 971 participants found that combined vitamin K and vitamin D supplementation was associated with higher total bone mineral density and lower undercarboxylated osteocalcin. The pooled evidence therefore supports an effect on bone-related markers and possibly BMD in the populations represented.
The underlying trials were heterogeneous in dose, vitamin K form, population and co-supplementation. A pooled positive effect therefore should not be treated as evidence that every vitamin D user benefits from adding vitamin K₂ or that all skeletal outcomes improve.
The 2026 VITAL analysis provides an important null counterweight
A 2026 ancillary analysis of the VITamin D and OmegA-3 TriaL examined whether baseline vitamin K status modified bone responses to vitamin D supplementation. The parent bone study had already found no significant two-year benefit of 2,000 IU vitamin D₃ daily on areal bone mineral density in generally healthy midlife and older adults.
In the ancillary analysis, vitamin K status was assessed using phylloquinone, undercarboxylated osteocalcin and dephosphorylated undercarboxylated MGP. Higher baseline vitamin K status was not associated with favourable two-year changes in spine, hip or whole-body BMD, trabecular bone score, volumetric BMD or peripheral bone architecture.
Most importantly for the proposed nutrient synergy, baseline vitamin K status did not modify the effect of supplemental vitamin D on areal BMD. Better vitamin K status therefore did not reveal a hidden skeletal benefit from vitamin D in this generally healthy population.
Vascular biomarkers provide another test of the interaction
The vascular rationale centres particularly on matrix Gla protein. MGP is an endogenous inhibitor of vascular calcification whose activity depends on vitamin-K-dependent carboxylation. High dp-ucMGP indicates a greater amount of inactive MGP and poorer functional vitamin K status.
Because vitamin D affects calcium and phosphate physiology, while vitamin K affects activation of MGP, it is plausible that combined supplementation could influence calcification biology. The clinical question is whether changing MGP status actually alters established vascular or valvular calcification.
The aortic-valve trial separated biomarker improvement from calcification outcome
A multicentre randomized double-blind trial enrolled 365 older men with substantial aortic-valve calcification. Participants received 720 µg MK-7 plus 25 µg vitamin D daily or placebo for 24 months.
The intervention produced a clear biochemical effect: dp-ucMGP fell substantially relative to placebo, demonstrating improved carboxylation status of this vitamin-K-dependent protein. Yet progression of aortic-valve calcification did not differ significantly between groups. Aortic valve area, peak jet velocity, coronary calcification, aortic calcification, surgery, cardiovascular events and mortality also showed no significant overall benefit.
This is one of the most important pieces of evidence in the entire vitamin D: vitamin K discussion. The expected biochemical target moved strongly, but the major structural calcification endpoint did not.
A coronary analysis suggested a possible high-calcification subgroup effect
A later analysis of the same trial examined coronary artery calcification. Across the overall coronary population, the difference in CAC progression between intervention and placebo was not statistically significant. Among participants starting with CAC scores of at least 400, progression was lower in the intervention group.
That subgroup result is potentially interesting but should not override the overall randomized outcome. Subgroup findings require replication and should not be converted into a general recommendation for combined supplementation to prevent vascular calcification.
Pediatric dialysis evidence shows biomarker responsiveness in another setting
A four-group randomized trial in 60 paediatric haemodialysis patients compared vitamin K₂, native vitamin D, combined K₂ plus vitamin D, and standard therapy. After four months, the combined group showed the strongest reductions in dp-ucMGP and undercarboxylated osteocalcin, while FGF23 did not change.
The study supports biological responsiveness of vitamin-K-dependent calcification markers in a high-risk renal population. But paediatric dialysis physiology is highly specialised and cannot be extrapolated directly to healthy adults. Renal mineral metabolism, phosphate burden and vascular calcification risk are substantially different, which is why Vitamin D and Kidneys remains an important contextual destination.
Biomarker improvement is not equivalent to prevention of calcification
The recurring pattern across vascular studies is that vitamin K supplementation can improve biochemical measures of vitamin-K-dependent protein activation. The harder question is whether those changes alter established disease progression.
The aortic-valve trial demonstrates that a large reduction in inactive MGP can coexist with no significant slowing of calcification. This does not make MGP irrelevant. It shows that calcification is governed by more than one pathway and may become partly irreversible or dominated by disease processes that persist despite improved vitamin K status.
Combined supplementation should not be presented as protection against vitamin D toxicity
Evidence that vitamin K activates MGP and osteocalcin has sometimes been extended into the claim that vitamin K protects against excessive vitamin-D-driven calcium exposure. Clinical trials do not establish that vitamin K supplementation prevents vitamin D toxicity or hypercalcaemia.
The mechanisms of excessive vitamin D signalling and calcium dysregulation are covered separately in Vitamin D Toxicity and Hypercalcaemia. Vitamin K-dependent protein biology should not be used to minimise those risks.
What the clinical evidence supports
Combined vitamin D and vitamin K interventions can improve vitamin-K-dependent biomarkers, particularly undercarboxylated osteocalcin and dp-ucMGP. Some osteoporosis trials and meta-analytic evidence support improvements in bone mineral density in selected populations.
The evidence does not establish a consistent skeletal benefit in generally healthy adults, does not show that better vitamin K status makes vitamin D supplementation prevent bone loss, and does not demonstrate that MK-7 plus vitamin D slows established aortic-valve calcification overall.
For integration of the mechanism, bone evidence and vascular null findings, see Vitamin D and Vitamin K in Calcium Handling, Bone and Vascular Physiology: Evidence Synthesis.
Scientific sources
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. PMID: 11180916.
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. PMID: 21860562.
The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials. PMID: 32219282.
Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL. PMID: 42524357.
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. PMID: 35465686.
The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. PMID: 34845313.
Related reading
Advanced glycation end products are not associated with bone mineral density, trabecular bone score, and bone turnover markers in adults with and without type 1 diabetes: a cross-sectional study
In participants with T1D, correlations between skin and serum AGEs as well as between AGEs and 3-year HbA1C were evaluated using Spearman’s correlations.
Original paper ↗Read more →Age-dependent bone mineral density responses to gender-affirming hormone therapy in transgender individuals: a one-year prospective study
Individuals assigned male at birth (AMAB) often show reduced bone mineral density (BMD) even before GAHT, whereas findings in those assigned female at birth (AFAB) are more variable.
Original paper ↗Read more →Association between bone turnover markers, bone mineral density, and serum osteoglycine in middle-aged men with Type 2 Diabetes mellitus
Data was compared among subjects and statistical analysis was performed.
Original paper ↗Read more →Association Between Mandibular Cortical Erosion and Bone Mineral Density Assessed by Phalangeal Ultrasound and Dual Energy X-Ray Absorptiometry in Spanish Women
Our results revealed that, compared with moderate cortical erosion, all the BMD measures had better AUCs when identifying severe cortical erosion.
Original paper ↗Read more →Bone mineral density and bone remodeling markers in chronic low back pain patients with active discopathy: A case-control exploratory study
We aimed to compare bone mineral density (BMD) and bone remodeling markers in chronic low back pain (cLBP) patients with and without active discopathy (Modic 1 changes).
Original paper ↗Read more →Bone Mineral Density in HIV-Infected People-the Experience of Craiova Regional Center
Human Immunodeficiency Virus (HIV) is a virus that progressively impairs immune function by depleting CD4 + T-lymphocytes, ultimately leading to acquired immunodeficiency syndrome (AIDS).
Original paper ↗Read more →Circulating irisin is linked to bone mineral density in geriatric Chinese men
While there is evidence of a link between irisin and bone metabolism, prior clinical evaluations have been limited to women with postmenopausal osteoporosis.
Original paper ↗Read more →Computed tomography-measured trabecular attenuation at first lumbar vertebra as a surrogate marker of bone mineral density and osteoporosis in patients undergoing hemodialysis
We examined the association between computed tomography (CT)-measured trabecular attenuation at the first lumbar vertebra (L1 CT-attenuation), bone mineral density (BMD), and osteoporosis in patients on hemodialysis.
Original paper ↗Read more →Early Initiation of Smoking and Alcohol Drinking as a Predictor of Lower Forearm Bone Mineral Density in Late Adolescence: A Cohort Study in Girls
Evaluations were conducted when participants were 13 and 17 years old.
Original paper ↗Read more →Factors Contributing to Improved Bone Mineral Density in Patients With Transfusion‐Dependent Thalassemia
This study aimed to identify endocrine complications, factors associated with endocrine complications, and changes in bone mineral density (BMD) in patients with transfusion‐dependent thalassemia (TDT).
Original paper ↗Read more →Interrelationships between sarcopenia, bone turnover markers and low bone mineral density in patients on hemodialysis
Patients who underwent regular HD at the First Affiliated Hospital of Soochow University were retrospectively evaluated.
Original paper ↗Read more →Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures
Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3%) and left femoral neck (2.2%), with an upward trend for total left hip (p=0.069).
Original paper ↗Read more →Novel association between atherogenic index of plasma and bone mineral density in men: a retrospective analysis
This study aimed to investigate the association between the atherogenic index of plasma (AIP), lipid parameters, and bone mineral density (BMD) in men with osteoporosis.
Original paper ↗Read more →Prevalence of vitamin D inadequacy and bone turnover markers concerning bone mineral density in older persons
We aimed to assess the prevalence of vitamin D deficiency and bone turnover marker concerning bone mineral density.
Original paper ↗Read more →Relationship between sex hormone levels, bone mineral density and bone turnover markers in healthy moroccan men: a cross-sectional study
The aim of this study is to evaluate the relationship of sex hormone levels, bone mineral density and biochemical markers of bone turnover in healthy Moroccan men.
Original paper ↗Read more →Relationship of matrix Gla protein and vitamin K with vascular calcification in hemodialysis patients
This study evaluated associations of serum matrix Gla protein (MGP), plasma vitamin K1, and plasma vitamin K2 with coronary artery calcium score (CACS) and cardiovascular disease (CVD) in maintenance hemodialysis (MHD) patients.
Original paper ↗Read more →Suboptimal Plasma Vitamin C Is Associated with Lower Bone Mineral Density in Young and Early Middle-Aged Men: A Retrospective Cross-Sectional Study
Background: This study was conducted to evaluate associations between bone mineral density (BMD) and four selected circulating nutrients, particularly vitamin C, among adults aged 20 to 49 years.
Original paper ↗Read more →Testosterone status and bone mineral density in Finnish male endurance athletes: Baseline associations and 1‐year follow‐up
This study examined whether low‐normal serum total testosterone (T) is associated with bone mineral density (BMD) or bone stress injuries (BSI) in male endurance athletes.
Original paper ↗Read more →The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial
They were randomised to 3 treatment arms; vitamin K1 (1 mg/day) arm, vitamin K2 arm (MK-4; 45 mg/day) or placebo for 18 months.
Original paper ↗Read more →The Effect of Clothing on Vitamin D Status, Bone Turnover Markers, and Bone Mineral Density in Young Kuwaiti Females
The aim of this study is to determine whether the clothing style of Kuwaiti premenopausal women affects their vitamin D status, bone marker expression, and bone density.
Original paper ↗Read more →Vitamin D levels and bone mineral density of middle-aged premenopausal female football and volleyball players in Japan: a cross-sectional study
This study aimed to determine the bone mineral density and vitamin D levels in middle-aged premenopausal female football players.
Original paper ↗Read more →Original sources
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
Publication details
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. PMID: 11180916.
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old.
Publication details
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. PMID: 21860562.
The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials
The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials.
Publication details
The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials. PMID: 32219282.
Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL
Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL.
Publication details
Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL. PMID: 42524357.
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial.
Publication details
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. PMID: 35465686.
The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial
The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis.
Publication details
The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. PMID: 34845313.